MX2023007299A - Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta. - Google Patents
Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.Info
- Publication number
- MX2023007299A MX2023007299A MX2023007299A MX2023007299A MX2023007299A MX 2023007299 A MX2023007299 A MX 2023007299A MX 2023007299 A MX2023007299 A MX 2023007299A MX 2023007299 A MX2023007299 A MX 2023007299A MX 2023007299 A MX2023007299 A MX 2023007299A
- Authority
- MX
- Mexico
- Prior art keywords
- tcr alpha
- cell recruiting
- polypeptides based
- reactivity
- beta
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 230000009257 reactivity Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente tecnología proporciona polipéptidos de reclutamiento de células T que se unen específicamente al dominio constante de un TCR humano y de primate no humano. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones. Los polipéptidos se pueden usar en métodos para el tratamiento del cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20306608 | 2020-12-18 | ||
EP2021086556 | 2021-12-17 | ||
EP21306822 | 2021-12-17 | ||
PCT/EP2021/086843 WO2022129637A1 (en) | 2020-12-18 | 2021-12-20 | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007299A true MX2023007299A (es) | 2023-07-04 |
Family
ID=79602034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007299A MX2023007299A (es) | 2020-12-18 | 2021-12-20 | Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240092919A1 (es) |
EP (1) | EP4263610A1 (es) |
KR (1) | KR20230122084A (es) |
AU (1) | AU2021402090A1 (es) |
CA (1) | CA3203141A1 (es) |
CO (1) | CO2023006691A2 (es) |
IL (1) | IL303740A (es) |
MX (1) | MX2023007299A (es) |
TW (1) | TW202241948A (es) |
WO (1) | WO2022129637A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202342508A (zh) * | 2021-12-17 | 2023-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向TCRαβ、CD33和CD123的免疫球蛋白單可變結構域的多肽 |
US20240109965A1 (en) * | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69334305D1 (de) | 1992-08-21 | 2010-01-28 | Univ Bruxelles | Immunoglobuline ohne leichte Ketten |
WO1994029457A2 (en) | 1993-06-09 | 1994-12-22 | Unilever N.V. | Process for producing fusion proteins comprising scfv fragments by a transformed mould |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6670453B2 (en) | 1997-10-27 | 2003-12-30 | Unilever Patent Holdings B.V. | Multivalent antigen-binding proteins |
WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
PT1071752E (pt) | 1998-04-21 | 2003-11-28 | Micromet Ag | Polipeptidos especificos para cd19xcd3 e suas utilizacoes |
US7958021B2 (en) | 2002-09-10 | 2011-06-07 | Igt | Method and device for collecting and reporting data |
NZ563471A (en) | 2002-11-08 | 2009-04-30 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
EP2267027A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
EP2215123A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Immunoglobulin constructs |
AU2010243551B2 (en) | 2009-04-30 | 2015-03-26 | Ablynx Nv | Method for the production of domain antibodies |
HUE051430T2 (hu) | 2009-07-10 | 2021-03-01 | Ablynx Nv | Eljárás variábilis domének elõállítására |
WO2012056000A1 (en) | 2010-10-29 | 2012-05-03 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
EP4218933A1 (en) | 2011-06-23 | 2023-08-02 | Ablynx NV | Serum albumin binding proteins |
CN108663504B (zh) | 2011-06-23 | 2021-06-22 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
PL3143042T3 (pl) | 2014-05-16 | 2020-11-16 | Ablynx N.V. | Domeny zmienne immunoglobuliny |
RS59376B1 (sr) | 2015-05-13 | 2019-11-29 | Ablynx Nv | Polipeptidi koji regrutuju t-ćelije na bazi tcr-alfa/beta reaktivnosti |
EP3974449A1 (en) | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
CA3005488A1 (en) | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
MX2019005696A (es) | 2016-11-16 | 2019-08-14 | Ablynx Nv | Polipeptidos de reclutamiento de celulas t capaces de unir cd123 y tcr alfa/beta. |
IL266907B1 (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Immunoglobulin sites with a single variable enhance serum albumin binding |
CN117285623A (zh) | 2017-01-17 | 2023-12-26 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合物 |
CN110461870B (zh) | 2017-01-17 | 2023-09-29 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合物 |
-
2021
- 2021-12-20 WO PCT/EP2021/086843 patent/WO2022129637A1/en active Application Filing
- 2021-12-20 AU AU2021402090A patent/AU2021402090A1/en active Pending
- 2021-12-20 TW TW110147792A patent/TW202241948A/zh unknown
- 2021-12-20 CA CA3203141A patent/CA3203141A1/en active Pending
- 2021-12-20 EP EP21843677.2A patent/EP4263610A1/en active Pending
- 2021-12-20 IL IL303740A patent/IL303740A/en unknown
- 2021-12-20 MX MX2023007299A patent/MX2023007299A/es unknown
- 2021-12-20 KR KR1020237024066A patent/KR20230122084A/ko unknown
- 2021-12-20 US US18/267,257 patent/US20240092919A1/en active Pending
-
2023
- 2023-05-23 CO CONC2023/0006691A patent/CO2023006691A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3203141A1 (en) | 2022-06-23 |
EP4263610A1 (en) | 2023-10-25 |
TW202241948A (zh) | 2022-11-01 |
WO2022129637A1 (en) | 2022-06-23 |
IL303740A (en) | 2023-08-01 |
US20240092919A1 (en) | 2024-03-21 |
WO2022129637A8 (en) | 2023-08-10 |
AU2021402090A9 (en) | 2024-05-16 |
KR20230122084A (ko) | 2023-08-22 |
AU2021402090A1 (en) | 2023-08-03 |
CO2023006691A2 (es) | 2023-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007299A (es) | Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta. | |
PH12020551932A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
MX2022009947A (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. | |
NZ750005A (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
CR20200465A (es) | Agentes anticuerpos anti-cd25 | |
JOP20200307A1 (ar) | جزيئات ربط ضد bcma واستخداماتها | |
MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
MX2022000726A (es) | Anticuerpos inmunomoduladores y metodos de uso de los mismos. | |
NZ709318A (en) | Antibody constructs for cdh19 and cd3 | |
NZ582018A (en) | Multipotent/pluripotent cells and methods | |
EP3611192A3 (en) | T cell recruiting polypeptides based on tcr alpha/beta reactivity | |
SG10201906460PA (en) | Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region | |
MX2020003339A (es) | Arn guía de cpf1 modificado. | |
MX2020007495A (es) | Formulacion de adenovirus del grupo b. | |
BR112022011072A2 (pt) | Intensificação de célula imune efetora derivada de ipsc usando compostos pequenos | |
BR112023014980A2 (pt) | Lentivírus para gerar células que expressam o receptor de antígeno quimérico anti-cd19 | |
EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
PH12020551454A1 (en) | Anti-cd25 for tumour specific cell depletion | |
MX2020011298A (es) | Composiciones de antígeno micobacteriano y métodos de uso. | |
MX2020009478A (es) | Compuestos y sus usos para tratar tumores en un paciente. | |
WO2018144777A3 (en) | Calreticulin-mediated cancer treatment | |
GIYNAŞ | ARAPÇA-FARSÇA-TÜRKÇE MANZUM BİR SÖZLÜK: TUHFETÜ'L-İHVÂN VE HEDİYYETÜ'SSIBYÂN. | |
MX2022004218A (es) | Proteina de fusion multiespecifica y uso de la misma. | |
Muster | How do MeteoSwiss communicate information about the effects of natural events? |